Peer-reviewed veterinary case report
Safety and weight effects of LY2190416 in young beagle dogs
By Nunamaker, E et al.·Published in Journal of veterinary pharmacology and therapeutics·2011·Purdue University School of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety evaluation and treatment affect of LY2190416, a CB-1 antagonist/inverse agonist in growing beagle dogs.
- Species:
- dog
Plain-English summary
A group of young beagle dogs was given a medication called LY2190416 to see if it could help manage weight gain without affecting their appetite. Over 13 weeks, while all the dogs continued to eat their full daily food allowance, those receiving the medication gained weight more slowly compared to the dogs that didn't get it. The treatment was found to be safe, with no significant health issues reported. This suggests that LY2190416 could be a helpful option for controlling weight gain in dogs without causing them to eat less.
People also search for: beagle weight gain treatment · dog obesity medication · LY2190416 for dogs
Abstract
The objective of this study was to assess the safe use of LY2190416, a cannabinoid receptor 1 receptor antagonist/inverse agonist, for obesity management in dogs. Twenty-four clinically normal young beagle dogs were administered LY2190416 at doses of 3, 9, or 18 mg/kg or placebo, orally, once daily for 13 weeks. Food consumption and body weight were determined, and dogs were evaluated for changes in hematology, clinical chemistry, urinalysis, and serum cortisol. LY2190416 had no significant effect on hematology, clinical chemistry, urinalysis, and serum cortisol. All dogs consumed 100% of their entire daily allowance throughout the study. All dogs gained weight during the study, but treated dogs gained less than control dogs by the end of the study. During the first month, dogs exhibited a dose-dependent decrease in rate of weight gain (19.7 g/day for control dogs vs. 10.6 g/day for the 18 mg/kg dose group). LY2190416 was found to be safe at doses up to 18 mg/kg administered daily for 3 months. Results suggest that LY2190416 decreases rate of weight gain without affecting appetite or causing significant adverse health effects in normal growing dogs. Possible mechanisms for a proposed metabolic effect are discussed.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21323931/